In a joint announcement, Dedalus Group and Ibex Medical Analytics revealed the launch of a fully integrated End-to-End AI-powered Digital Pathology Solution for cancer diagnosis. As the leading anatomic pathology information systems provider in Europe, Dedalus aims to set a new standard for anatomic pathology lab digitisation by seamlessly integrating Ibex's Galen™ platform into Dedalus' comprehensive Digital Pathology (DP) Solution. This collaborative effort responds to the growing demand for pathology services due to an increasing number of cancer patients and a global shortage of trained pathologists.
The integrated solution, now commercially available in major European markets, offers a next-generation Anatomic Pathology Information System (AIS) & DP solution. It harnesses the power of data and AI for assisted case prioritisation, advanced image analysis, and reproducible diagnoses. With a focus on efficiency and maintaining high accuracy levels, the solution addresses the challenges posed by the shortage of pathologists, reducing the time to diagnosis and optimising diagnostic workflows. The integration of Ibex's Galen™ AI technology allows for improved accuracy in diagnosing prostate, breast, and gastric biopsies, along with AI-powered decision support tools, streamlined reporting, enhanced laboratory efficiency, and increased diagnostic confidence.
Marlen Suller, Head of In Vitro Diagnostics Business Unit at Dedalus, expressed pride in the collaboration with Ibex, emphasising the commitment to advancing anatomic pathology and providing pathologists with a state-of-the-art solution. Joseph Mossel, CEO and Co-founder of Ibex Medical Analytics, highlighted the partnership's significance in embedding AI within Dedalus' information system, offering an end-to-end solution that combines AI findings with digital images, patient information, and lab processes in a unified workflow.
Click here to read the original news story.